Takeda Pharmaceutical Co Ltd
TSE:4502
Operating Margin
Takeda Pharmaceutical Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| JP |
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
7T JPY |
10%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
779.4B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
394B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
233.4B CHF |
32%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
174.8B GBP |
23%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
198.5B CHF |
32%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
225.9B USD |
36%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.8B USD |
25%
|
Takeda Pharmaceutical Co Ltd
Glance View
In the ever-evolving landscape of global pharmaceuticals, Takeda Pharmaceutical Co Ltd. stands as a robust and adaptive entity, blending a rich heritage with bold innovation. Originating from Japan, Takeda's journey began over two centuries ago, carving its niche by focusing on value-driven and research-led approaches in the pharmaceutical industry. With its headquarters in Tokyo, the company has fortified its position as one of the global leaders, largely due to its emphasis on research and development that spans across cutting-edge areas such as oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. This innovation-centric strategy is not just a nod to the future, but a crucial component that allows Takeda to address pressing health challenges worldwide, continually expanding its pipeline with transformative therapies. Takeda's commercial model revolves around its diverse therapeutic portfolio and strategic collaborations, which are instrumental in capturing growth across various markets. By leveraging its scientific expertise and expanding technological capabilities, the company advances its core business segments while integrating augmented biotechnology solutions through strategic acquisitions and partnerships. The absorption of Shire, a prominent biotechnology firm, stands as a hallmark of Takeda's commitment to enhancing its presence in rare diseases and plasma-derived therapies, thereby widening its global footprint. This focus not only fuels revenue generation from innovative products but also ensures a multidimensional approach to market entry across pivotal regions. Through balancing its inventive drive with operational efficiency, Takeda efficiently monetizes its products, securing its status as a formidable player in the pharmaceutical domain.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Takeda Pharmaceutical Co Ltd's most recent financial statements, the company has Operating Margin of 10.5%.
You don't have any saved screeners yet